Stoke Therapeutics (NASDAQ:STOK) Hits New 1-Year High - Still a Buy?

Key Points

• Stoke Therapeutics shares reached a new 52-week high of $21.87, with analysts maintaining a generally positive outlook, as two analysts rated it a Strong Buy and seven a Buy.
• The company reported earnings of ($0.40) per share, exceeding expectations, but still fell short on revenue with $13.82 million against an anticipated $31.51 million.
• Insiders have recently sold a significant amount of stock, totaling over $2 million in transactions, leading to a decreased ownership stake among them.

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) shares reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $21.80 and last traded at $21.87, with a volume of 282065 shares traded. The stock had previously closed at $20.68.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on STOK shares. Chardan Capital reiterated a "buy" rating and set a $24.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, August 13th. Cantor Fitzgerald raised shares of Stoke Therapeutics to a "strong-buy" rating in a report on Wednesday, May 14th. Jefferies Financial Group assumed coverage on shares of Stoke Therapeutics in a report on Friday, July 18th. They issued a "buy" rating and a $30.00 price target on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $22.00 price target on shares of Stoke Therapeutics in a report on Tuesday, July 1st. Finally, HC Wainwright cut their price target on shares of Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Two analysts have rated the stock with a Strong Buy rating and seven have given a Buy rating to the company. Based on data from MarketBeat, Stoke Therapeutics presently has an average rating of "Buy" and a consensus price target of $25.57.

Stoke Therapeutics Trading Up 7.1%

The stock's 50-day moving average price is $14.92 and its 200-day moving average price is $11.06. The company has a market capitalization of $1.21 billion, a P/E ratio of 26.05 and a beta of 1.14.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.57) by $0.17. Stoke Therapeutics had a net margin of 26.25% and a return on equity of 18.32%. The business had revenue of $13.82 million for the quarter, compared to analysts' expectations of $31.51 million. Sell-side analysts expect that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Stoke Therapeutics news, General Counsel Jonathan Allan sold 6,345 shares of the firm's stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $20.07, for a total transaction of $127,344.15. Following the transaction, the general counsel owned 11,831 shares of the company's stock, valued at approximately $237,448.17. This trade represents a 34.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Edward M. Md Kaye sold 45,996 shares of the firm's stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $20.13, for a total transaction of $925,899.48. Following the transaction, the director directly owned 91,585 shares in the company, valued at approximately $1,843,606.05. The trade was a 33.43% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 107,719 shares of company stock valued at $2,063,359 in the last quarter. Company insiders own 9.50% of the company's stock.

Hedge Funds Weigh In On Stoke Therapeutics

Hedge funds have recently made changes to their positions in the business. Wellington Management Group LLP boosted its holdings in shares of Stoke Therapeutics by 0.9% in the first quarter. Wellington Management Group LLP now owns 135,960 shares of the company's stock worth $904,000 after buying an additional 1,148 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Stoke Therapeutics by 5.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company's stock worth $162,000 after purchasing an additional 1,149 shares during the period. Graham Capital Management L.P. boosted its holdings in shares of Stoke Therapeutics by 8.5% during the fourth quarter. Graham Capital Management L.P. now owns 18,634 shares of the company's stock worth $206,000 after purchasing an additional 1,453 shares during the period. BNP Paribas Financial Markets lifted its stake in Stoke Therapeutics by 66.2% in the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company's stock valued at $48,000 after acquiring an additional 1,668 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in Stoke Therapeutics by 14.1% in the second quarter. The Manufacturers Life Insurance Company now owns 15,099 shares of the company's stock valued at $171,000 after acquiring an additional 1,862 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.